ReviewMatrix biology : journal of the International Society for Matrix Biology2012
Molecular functions of syndecan-1 in disease.
Review in Matrix biology : journal of the International Society for Matrix Biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 2 syntheses or guidelines pooled it, 353 citations in OpenAlex.
- Early biomarkers for prediction of severe manifestations of dengue fever: a systematic review and a meta-analysis.Scientific reports · 2023Pooled it
- Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023Pooled it
- Plasma growth differentiation factor-15 is associated with cardiovascular events in patients hospitalized for acute exacerbation of COPD.Scientific reports · 2026Trial
- Trial
- Distinct immunometabolic signatures in peripheral blood mononuclear cells are linked to systemic inflammation in type 2 diabetes and diabetic kidney disease.Molecular biomedicine · 2026Article
- Membrane-type I metalloproteinase (MT1-MMP): A key modifier of extracellular matrix microenvironment.The FEBS journal · 2026Review
- Article
- Heparan Sulfate Proteoglycans in Immunity.Proteoglycan research · 2026Article
- Syndecan-1 Promotes Alveolar Type 2 Epithelial Cell Senescence during Lung Fibrosis.bioRxiv : the preprint server for biology · 2026Article
- Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells in systemic lupus erythematosus and averts glomerular pathology.bioRxiv : the preprint server for biology · 2026Article
- Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease.Science advances · 2026Article
- Early plasma syndecan-1 dynamics and their prognostic value in major thoracic and abdominal surgery: a prospective observational study.Perioperative medicine (London, England) · 2026Article
- Endothelial glycocalyx thickness in cats with naturally occurring trauma or non-traumatic illness: an exploratory study.Frontiers in veterinary science · 2026Article
- Article
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- Comparative transcriptomic and machine learning analysis identifies key genes and immune dysregulation in goats exposed to peste des petits ruminants virus.Virus genes · 2025Article
- Association of Visceral Fat Accumulation with Endothelial Glycocalyx Degradation in People with and without Type 2 Diabetes: A Retrospective Cross-sectional Study.Journal of atherosclerosis and thrombosis · 2025Article
- Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet's Disease.Archives of rheumatology · 2025Article
- Epithelial Heparan Sulfate PromotesProteoglycan research · 2025Article
- Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study.Breast cancer research and treatment · 2025Article
140 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Syndecan-1 is a cell surface heparan sulfate proteoglycan that binds to many mediators of disease pathogenesis. Through these molecular interactions, syndecan-1 can modulate leukocyte recruitment, cancer cell proliferation and invasion, angiogenesis, microbial attachment and entry, host defense mechanisms, and matrix remodeling. The significance of syndecan-1 interactions in disease is underscored by the striking pathological phenotypes seen in the syndecan-1 null mice when they are challenged with disease-instigating agents or conditions. This review discusses the key molecular functions of syndecan-1 in modulating the onset, progression, and resolution of inflammatory diseases, cancer, and infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.